MORRISTOWN, N.J., Dec. 20 /PRNewswire/ -- Dr. Arthur L. Caplan, PhD will be the keynote speaker at the sixth annual Therapeutic Insight Conference. Therapeutic Insight 2006 (“TI2006") will take place on April 25 and 26, 2006, at the Ritz-Carlton, Boston.
Dr. Caplan’s Keynote is entitled, Good, Better, Best?: The Ethics of Improvement and Enhancement That Face the Pharma and Biotech Industries. His comments will continue a dialogue that began at last year’s conference, when he raised the specter of a societal obligation to consider lifestyle drugs as one would any life-saving drug, as a matter of quality of life. In the spirit of previous Therapeutic Insight keynote presentations, Dr. Caplan’s observations are expected to lead to a provocative and constructive dialogue around a complex issue.
Dr. Caplan is Emmanuel and Robert Hart Professor of Bioethics, Center for Bioethics & Department of Medical Ethics, University of Pennsylvania. He is chair of the Department of Medical Ethics at University of Pennsylvania, in addition to serving as the Trustee Professor and Director of the University’s Center for Bioethics. Dr. Caplan is also a Professor in the Department of Philosophy and in the Department of Psychiatry in the School of Medicine. He is the author or editor of more than twenty books and over 500 papers in refereed journals, has written a weekly newspaper column on bioethics for the Hearst/King Features syndicate and currently writes a regular column on bioethics for MSNBC.com.
Other TI2006 speakers to date include: Karen Bernstein, PhD, Chairman & Editor-In-Chief, BioCentury Alexis Borisy, AM, President & Chief Executive Officer, CombinatoRx Michael D. Clayman, MD, VP, Lilly Research Laboratories Bruce Cohen, President & CEO, Cellerant Therapeutics David DeMarco, PhD, Vice President, Strategic Planning, Cambrex Frederick Frank, Vice Chairman & Director, Lehman Brothers Robert H. Glassman, MD, Director, Healthcare Investment Banking, Merrill Lynch Mitchell H. Gold, MD, President & CEO, Dendreon Juergen Lasowski, VP, Head of Business Development & Strategy, US, Sanofi- Aventis Brian Leyland-Jones, MD, Professor & Founding Chairman, Department of Oncology, McGill University Clive A. Meanwell, MD, Chairman & CEO, The Medicines Company Paul C. Nakagaki, PhD, Head, Pharma Research Strategy, Pharmaceuticals Division, F. Hoffmann-La Roche Ltd. Roger S. Newton, PhD, Sr. VP, PGRD, Director, Esperion Therapeutics Division of Pfizer Global Research & Development Douglas E. Onsi, VP Business Development, Genzyme Genetics Richard Pasternak, MD, VP, Clinical Research Cardiovascular/Atherosclerosis, Merck Research Laboratories Paul M. Ridker, MD, MPH, Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital Robert E. Ward, Sr. Director Commercial Development, Biologics & Small Molecules, Schering-Plough
Therapeutic Insight 2006 is sponsored by Defined Health and Communitech Market Intelligence. To register, or for more information, please visit www.therapeuticinsight.com, or contact Communitech: (914) 245-7764, www.cmius.com, or Defined Health (973) 292-5001, www.definedhealth.com.
Contact: Ginny E. Llobell Vice President Defined Health 973-292-5001
Defined Health
CONTACT: Ginny E. Llobell, Vice President, Defined Health, +1-973-292-5001
